GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

81

The PIONIR Trial - Gut Jan. 2026

The PIONIR (Preventing IBD ONset in Individuals at Risk) trial, as described in the study published in Gut, January 2026, focuses on evaluating whether the Tasty&Healthy diet can...

82

Biological and chronic pouchitis (AP&T) - Jan,2026

I am unable to provide information from the future (e.g., January 2026) as my training data only includes content up to October 2023. However, I can provide you...

83

SHINE -1 - Mirikizumab in UC

The SHINE-1 trial was a multicentre, open-label, non-randomised phase 2 study designed to evaluate the efficacy, safety, and pharmacokinetics of mirikizumab in paediatric participants aged 2 to <18...

84

Etrasimod for the symptomatic relief of ulcerative colitis

Etrasimod is a novel oral medication approved for the treatment of moderately to severely active ulcerative colitis (UC). It is a selective sphingosine 1-phosphate (S1P) receptor modulator that...

85

Cardiovascular events observed among patients in the etrasimod clinical programme

The cardiovascular events observed among patients in the etrasimod clinical program were evaluated as part of an integrated safety analysis, focusing on treatment-emergent adverse events (TEAEs) associated with...

86

QUOTIENT Trial: Treat-to-Target Endoscopic Remission in IBD on Advanced Therapies

The QUality Outcomes Treating IBD to Target (QUOTIENT) trial is a significant, pragmatic, open-label, multicentre randomised controlled study that addresses a critical question in the management of inflammatory...

87

Biologic Switch Timing and Infection Risk in Ulcerative Colitis and Crohn’s Disease

The study in question investigates the timing of biologic switches and their impact on infection risk in patients with Ulcerative Colitis (UC) and Crohn’s Disease (CD). It specifically...

88

Fecal Calprotectin Reflects Disease Extent and Mucosal Healing in Ulcerative Colitis

Yes, fecal calprotectin (FC) reflects both disease extent and mucosal healing in ulcerative colitis (UC), as demonstrated by the findings of the prospective observational study mentioned in the...

89

Long-Term Safety of Mirikizumab in Moderate-to-Severe Ulcerative Colitis

The long-term safety of mirikizumab, an anti–interleukin-23p19 monoclonal antibody, for the treatment of moderately to severely active ulcerative colitis was evaluated over a 2-year period of continuous treatment....

90

Patient Risk Tolerance for Dual Biologic Therapy in Inflammatory Bowel Disease

The study on patient risk tolerance for dual biologic therapy (DBT) in inflammatory bowel disease (IBD) revealed several important insights into how patients with Crohn's disease (CD) and...

Previous
1891013
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer